Clinical guidelines need high-quality studies to support clinical decision making, in which the evidence often was collected from systematic reviews (SRs) and/or meta-analyses (MAs). At present, the methodological quality and risk of bias (RoB) of SRs/MAs on stem cell therapy for the treatment of knee osteoarthritis (KOA) has been poorly investigated. This study aims to strictly evaluate the methodological quality and RoB in SRs/MAs of stem cell therapy for KOA. Four electronic databases (PubMed, Embase, Cochrane Library, and Web of Science databases) were searched, from inception to October 5, 2021. SRs/MAs involving randomized control trials or cohort studies on stem cell therapy for the treatment of KOA were included. The methodological quality and RoB were assessed using AMSTAR 2 and ROBIS tool, respectively. In total, 22 SRs/MAs were included. According to the results obtained by AMSTAR 2 tool, all SRs/MAs were rated as “Critically low.” Main methodological weaknesses were as follows: up to 81.82% did not meet protocol registration requirements, only 13.64% provided a list of excluded studies and justification, and 13.64% investigated and discussed the publication bias. ROBIS-based RoB assessment showed that all the SRs/MAs were rated as “High.” Besides, the lack of following the implementation of the PRISMA reporting guideline seems to reduce the methodological quality of the studies. The overall methodological quality of the SRs/MAs concerning the application of stem cell therapy in treating KOA is “Critically low,” while the RoB is high. It is difficult to provide effective evidence for the formulation of guidelines for KOA treatment. We suggest that the relevant methodological quality assessment should be carried out in the future before the SRs/MAs are used as clinical evidence. In addition, it may be necessary for many journals to include the checklist with a submitted article.
PROSPERO registration number: CRD42021246924
Get full access to this article
View all access options for this article.
References
1.
HunterDJ and Bierma-ZeinstraS. (2019). Osteoarthritis. Lancet, 393:1745–1759.
2.
CrossM, SmithE, HoyD, NolteS, AckermanI, FransenM, BridgettL, WilliamsS, GuilleminF, et al. (2014). The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis, 73:1323–1330.
3.
DeshpandeBR, KatzJN, SolomonDH, YelinEH, HunterDJ, MessierSP, SuterLG and LosinaE. (2016). Number of persons with symptomatic knee osteoarthritis in the US: impact of race and ethnicity, age, sex, and obesity. Arthritis Care Res (Hoboken), 68:1743–1750.
4.
LiD, LiS, ChenQ and XieX. (2020). The prevalence of symptomatic knee osteoarthritis in relation to age, sex, area, region, and body mass index in China: a systematic review and meta-analysis. Front Med (Lausanne), 7:304.
5.
BerenbaumF, WallaceIJ, LiebermanDE and FelsonDT. (2018). Modern-day environmental factors in the pathogenesis of osteoarthritis. Nat Rev Rheumatol, 14:674–681.
6.
RoosEM and ArdenNK. (2016). Strategies for the prevention of knee osteoarthritis. Nat Rev Rheumatol, 12:92–101.
7.
GallagherB, TjoumakarisFP, HarwoodMI, GoodRP, CiccottiMG and FreedmanKB. (2015). Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents. Am J Sports Med, 43:734–744.
8.
KolasinskiSL, NeogiT, HochbergMC, OatisC, GuyattG, BlockJ, CallahanL, CopenhaverC, DodgeC, et al. (2020). 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol, 72:220–233.
9.
GobbiA, DalloI, RogersC, StrianoRD, MautnerK, BowersR, RozakM, BilboolN and MurrellWD. (2021). Two-year clinical outcomes of autologous microfragmented adipose tissue in elderly patients with knee osteoarthritis: a multi-centric, international study. Int Orthop, 45:1179–1188.
10.
DalloI, SzwedowskiD, MobasheriA, IrlandiniE and GobbiA. (2021). A prospective study comparing leukocyte-poor platelet-rich plasma combined with hyaluronic acid and autologous microfragmented adipose tissue in patients with early knee osteoarthritis. Stem Cells Dev, 30:651–659.
11.
Kale VP. (2019). Application of “primed”. mesenchymal stromal cells in hematopoietic stem cell transplantation: current status and future prospects. Stem Cells Dev transplantation:1473–1479.
12.
VeronesiF, GiavaresiG, TschonM, BorsariV, Nicoli AldiniN and FiniM. (2013). Clinical use of bone marrow, bone marrow concentrate, and expanded bone marrow mesenchymal stem cells in cartilage disease. Stem Cells Dev, 22:181–192.
13.
DalloI, D'AmbrosiR, SzwedowskiD, MobasheriA and GobbiA. (2022). Minimally invasive cell-based therapy for symptomatic bone marrow lesions of the knee: a prospective clinical study at 1 year. Stem Cells Dev. [Epub ahead of print]; DOI: 10.1089/scd.2021.0283.
14.
PasHI, WintersM, HaismaHJ, KoenisMJ, TolJL and MoenMH. (2017). Stem cell injections in knee osteoarthritis: a systematic review of the literature. Br J Sports Med, 51:1125–1133.
15.
KimSH, HaCW, ParkYB, NamE, LeeJE and LeeHJ. (2019). Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of the knee: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg, 139:971–980.
16.
DaiW, LengX, WangJ, ShiZ, ChengJ, HuX and AoY. (2021). Intra-articular mesenchymal stromal cell injections are no different from placebo in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Arthroscopy, 37:340–358.
17.
Ioannidis JP. (2016). The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. Milbank Q, 94:485–514.
18.
BannuruRR, OsaniMC, VaysbrotEE, ArdenNK, BennellK, Bierma-ZeinstraSMA, KrausVB, LohmanderLS, AbbottJH, et al. (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 27:1578–1589.
19.
ArianiA, ManaraM, FioravantiA, IannoneF, SalaffiF, UghiN, PreveteI, BortoluzziA, ParisiS and ScirèCA. (2019). The Italian Society for Rheumatology Clinical Practice Guidelines for the diagnosis and management of knee, hip and hand osteoarthritis. Reumatismo, 71:5–21.
20.
Mulrow CD. (1994). Rationale for systematic reviews. BMJ, 309:597–599.
21.
XingD, WangQ, YangZ, HouY, ZhangW, ChenY and LinJ. (2018). Mesenchymal stem cells injections for knee osteoarthritis: a systematic overview. Rheumatol Int, 38:1399–1411.
22.
PieperD, BuechterRB, LiL, PredigerB and EikermannM. (2015). Systematic review found AMSTAR, but not R(evised)-AMSTAR, to have good measurement properties. J Clin Epidemiol, 68:574–583.
23.
SheaBJ, ReevesBC, WellsG, ThukuM, HamelC, MoranJ, MoherD, TugwellP, WelchV, KristjanssonE and HenryDA. (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 358:j4008.
24.
StormanM, StormanD, JasinskaKW, SwierzMJ and BalaMM. (2020). The quality of systematic reviews/meta-analyses published in the field of bariatrics: a cross-sectional systematic survey using AMSTAR 2 and ROBIS. Obes Rev, 21:e12994.
25.
WuIX, WangH, ZhuL, ChenY, WongCH, MaoC and ChungVC. (2020). Methodological quality of systematic reviews on interventions for osteoarthritis: a cross-sectional study. Ther Adv Musculoskelet Dis, 12:1759720X20959967.
26.
ZhangGQ, ChenJL, LuoY, MathurMB, AnagnostisP, NurmatovU, TalibovM, ZhangJ, HawrylowiczCM, et al. (2021). Menopausal hormone therapy and women's health: an umbrella review. PLoS Med, 18:e1003731.
27.
XuC, Furuya-KanamoriL, KwongJSW, LiS, LiuY and DoiSA. (2021). Methodological issues of systematic reviews and meta-analyses in the field of sleep medicine: a meta-epidemiological study. Sleep Med Rev, 57:101434.
28.
CumpstonM, LiT, PageMJ, ChandlerJ, WelchVA, HigginsJP and ThomasJ. (2019). Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev, 10:ED000142.
29.
WhitingP, SavovićJ, HigginsJP, CaldwellDM, ReevesBC, SheaB, DaviesP, KleijnenJ, ChurchillR and groupROBIS. (2016). ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol, 69:225–234.
30.
XiaP, WangX, LinQ and LiX. (2015). Efficacy of mesenchymal stem cells injection for the management of knee osteoarthritis: a systematic review and meta-analysis. Int Orthop, 39:2363–2372.
31.
CuiGH, WangYY, LiCJ, ShiCH and WangWS. (2016). Efficacy of mesenchymal stem cells in treating patients with osteoarthritis of the knee: a meta-analysis. Exp Ther Med, 12:3390–3400.
32.
YuboM, YanyanL, LiL, TaoS, BoL and LinC. (2017). Clinical efficacy and safety of mesenchymal stem cell transplantation for osteoarthritis treatment: a meta-analysis. PLoS One, 12:e0175449.
33.
IijimaH, IshoT, KurokiH, TakahashiM and AoyamaT. (2018). Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-analysis toward the establishment of effective regenerative rehabilitation. NPJ Regen Med, 3:15.
34.
DavidsonPA, BlandDS and HendersonM. (2018). A systematic review of the treatment of knee osteoarthritis with intraarticular injection of mesenchymal stem cells. Curr Orthop Pract, 29:590–596.
35.
ShinYS, YoonJR, KimHS and LeeSH. (2018). Intra-articular injection of bone marrow-derived mesenchymal stem cells leading to better clinical outcomes without difference in MRI outcomes from baseline in patients with knee osteoarthritis. Knee Surg Relat Res, 30:206–214.
36.
HaCW, ParkYB, KimSH and LeeHJ. (2019). Intra-articular mesenchymal stem cells in osteoarthritis of the knee: a systematic review of clinical outcomes and evidence of cartilage repair. Arthroscopy, 35:277–288.e2.
37.
MiglioriniF, RathB, ColarossiG, DriessenA, TingartM, NiewieraM and EschweilerJ. (2020). Improved outcomes after mesenchymal stem cells injections for knee osteoarthritis: results at 12-months follow-up: a systematic review of the literature. Arch Orthop Trauma Surg, 140:853–868.
38.
WangR, ZhaoL and HuangC. (2019). Clinical efficacy and cartilage repair effect of mesenchymal stem cells intra-articular injection for knee osteoarthritis: a meta-analysis of randomized control trials. Chin J Rheumatol, 23:803–809.
39.
HallM, McCaffertyJ, AgarwallaA, NwachukuI, LiuJN and AminNH. (2020). Safety and efficacy of cultured/noncultured mesenchymal stromal cells without concurrent surgery for knee osteoarthritis: a systematic review of randomized controlled trials. J Long Term Eff Med Implants, 30:31–47.
40.
HanX, YangB, ZouF and SunJ. (2020). Clinical therapeutic efficacy of mesenchymal stem cells derived from adipose or bone marrow for knee osteoarthritis: a meta-analysis of randomized controlled trials. J Comp Eff Res, 9:361–374.
41.
HuangR, LiW, ZhaoY, YangF and XuM. (2020). Clinical efficacy and safety of stem cell therapy for knee osteoarthritis: a meta-analysis. Medicine (Baltimore), 99:e19434.
42.
JeyaramanM, MuthuS and GaniePA. (2021). Does the source of mesenchymal stem cell have an effect in the management of osteoarthritis of the knee? Meta-analysis of randomized controlled trials. Cartilage, 13:1532S–1547S.
43.
KimSH, DjajaYP, ParkYB, ParkJG, KoYB and HaCW. (2020). Intra-articular injection of culture-expanded mesenchymal stem cells without adjuvant surgery in knee osteoarthritis: a systematic review and meta-analysis. Am J Sports Med, 48:2839–2849.
44.
MaW, LiuC, WangS, XuH, SunH and FanX. (2020). Efficacy and safety of intra-articular injection of mesenchymal stem cells in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Medicine (Baltimore), 99:e23343.
45.
WangJ, ZhouL, ZhangY, HuangL and ShiQ. (2020). Mesenchymal stem cells—a promising strategy for treating knee osteoarthritis. Bone Joint Res, 9:719–728.
46.
SongY, ZhangJ, XuH, LinZ, ChangH, LiuW and KongL. (2020). Mesenchymal stem cells in knee osteoarthritis treatment: a systematic review and meta-analysis. J Orthop Translat, 24:121–130.
47.
QuH and SunS. (2021). Efficacy of mesenchymal stromal cells for the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. J Orthop Surg Res, 16:11.
48.
TanSHS, KwanYT, NeoWJ, ChongJY, KuekTYJ, SeeJZF, WongKL, TohWS and HuiJHP. (2021). Intra-articular injections of mesenchymal stem cells without adjuvant therapies for knee osteoarthritis: a systematic review and meta-analysis. Am J Sports Med, 49:3113–3124.
49.
WakitaniS, ImotoK, YamamotoT, SaitoM, MurataN and YonedaM. (2002). Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage, 10:199–206.
50.
XuYG, HuJZ, WangY, LiBC, ZhuCM and WeiXM. (2009). Comparative study of bone marrow mesenchymal stem cells transplantation in the treatment of knee osteoarthritis. Chin J N Clin Med, 2:1250–1252. [Chinese].
51.
VarmaHS, DadaryaB and VidyarthiA. (2010). The new avenues in the management of osteo-arthritis of knee—stem cells. J Indian Med Assoc, 108:583–585.
52.
NejadnikH, HuiJH, Feng ChoongEP, TaiBC and LeeEH. (2010). Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med, 38:1110–1116.
53.
BhattacharyaN. (2011). Clinical use of amniotic fluid in osteoarthritis: a source of cell therapy. Transplantation, 90:395–403.
54.
KohYG and ChoiYJ. (2012). Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee, 19:902–907.
55.
WongKL, LeeKB, TaiBC, LawP, LeeEH and HuiJH. (2013). Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects undergoing high tibial osteotomy: a prospective, randomized controlled clinical trial with 2 years’ follow-up. Arthroscopy, 29:2020–2028.
56.
TanYH, JiangMM, YuHY, LiJL and QingZY. (2013). Therapeutic effect of arthroscopy combined with autologous bone marrow stem cell grafting on knee osteoarthritis. J Tradit Chin Orthop Traumatol, 10:35–38. [Chinese].
57.
SawKY, AnzA, Siew-Yoke JeeC, MericanS, Ching-Soong NgR, RoohiSA and RagavanaiduK. (2013). Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy, 29:684–694.
58.
KohYG, KwonOR, KimYS and ChoiYJ. (2014). Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study. Arthroscopy, 30:1453–1460.
59.
GanFY, TangC, GuoDB and XiaoLX. (2014). The treatment of mesenchymal stem cell transplantation for knee osteoarthritis: a clinical observation study. Modern Diagn Treat, 25:3512–3513. [Chinese].
60.
OrozcoL, MunarA and SolerR. (2014). Treatment of knee osteoarthritis with allogenic mesenchymal stem cells. https://www.clinicaltrials.gov. Identifier: NCT01586312.
61.
VangsnessCTJr, FarrJ2nd, BoydJ, DellaeroDT, MillsCR and LeRoux-WilliamsM. (2014). Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am, 96:90–98.
62.
AkgunI, UnluMC, ErdalOA, OgutT, ErturkM, OvaliE, KantarciF, CaliskanG and AkgunY. (2015). Matrix-induced autologous mesenchymal stem cell implantation versus matrix-induced autologous chondrocyte implantation in the treatment of chondral defects of the knee: a 2-year randomized study. Arch Orthop Trauma Surg, 135:251–263.
63.
LiangHS, HuangK, LiL, CaiM, HuangJZ, LongTF, YangW, LiangH and LiuL. (2015). Arthroscopic microfracture surgery combined with autologous bone marrow mesenchymal stem cells transplant in the treatment of knee cartilage defect. Chin J Mod Drug Appl, 9:1–3. [Chinese].
64.
LvXX, HuangC, YinZ, HongBG, JiangHJ and HuangXJ. (2015). Effectiveness of autologous bone marrow mesenchymal stem cell transplant for knee osteoarthritis. Chin J Cell Stem Cell, 5:28–32. [Chinese].
65.
VegaA, Martín-FerreroMA, Del CantoF, AlbercaM, GarcíaV, MunarA, OrozcoL, SolerR, FuertesJJ, et al. (2015). Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation, 99:1681–1690.
66.
GuptaPK, ChullikanaA, RengasamyM, ShettyN, PandeyV, AgarwalV, WaghSY, VellotarePK, DamodaranD, et al. (2016). Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint. Arthritis Res Ther, 18:301.
67.
Lamo-EspinosaJM, MoraG, BlancoJF, Granero-MoltóF, Nuñez-CórdobaJM, Sánchez-EcheniqueC, BondíaJM, AquerretaJD, AndreuEJ, et al. (2016). Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II). J Transl Med, 14:246.
68.
WangYL, JinWX, LiuHY, CuiYH, MaoQC, FeiZY and XiangCS. (2016). Curative effect of human umbilical cord mesenchymal stem cells by intra-articular injection for degenerative knee osteoarthritis. Chin J Reparative Reconstructive Surg, 30:1472–1477. [Chinese].
69.
YangXB, JiangF, ZhangF, ShiXF, LiuLM and XuZG. (2017). Therapeutic effect of human umbilical cord-derived mesenchymal stem cells for severe knee osteoarthritis. Chin J Clin Pharmacol Ther, 22:305–311. [Chinese].
70.
ShapiroSA, KazmerchakSE, HeckmanMG, ZubairAC and O'ConnorMI. (2017). A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am J Sports Med, 45:82–90.
71.
WangY, ShimminA, GhoshP, MarksP, LinklaterJ, ConnellD, HallS, SkerrettD, ItescuS and CicuttiniFM. (2017). Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial. Arthritis Res Ther, 19:180.
72.
Garay-MendozaD, Villarreal-MartínezL, Garza-BedollaA, Pérez-GarzaDM, Acosta-OlivoC, Vilchez-CavazosF, Diaz-HutchinsonC, Gómez-AlmaguerD, Jaime-PérezJC and Mancías-GuerraC. (2018). The effect of intra-articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis. Int J Rheum Dis, 21:140–147.
73.
JoCH, ChaiJW, JeongEC, OhS, ShinJS, ShimH and YoonKS. (2017). Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a 2-year follow-up study. Am J Sports Med, 45:2774–2783.
74.
EspinozaF, MatasJ, OrregoM, TapiaR, InfanteC, KhouryM and FigueroaFE. (2017). Allogeneic mesenchymal stromal cell (MSC) therapy for knee osteoarthritis (OA): a phase I/II randomized controlled trial. Cytotherapy, 19:24.
75.
KuahD, SivellS, LongworthT, JamesK, GuermaziA, CicuttiniF, WangY, CraigS, CominG, RobinsonD and WilsonJ. (2018). Safety, tolerability and efficacy of intra-articular Progenza in knee osteoarthritis: a randomized double-blind placebo-controlled single ascending dose study. J Transl Med, 16:49.
76.
HaCZ, LiW, RenSD, ZhouCH, ChenSF, WangDW and LiuC. (2018). Effect of platelet rich plasma combined with mesenchymal stem cells in treatment of knee osteoarthritis. Chin J Joint Surg (Electronic Edition), 12:644–652. [Chinese].
77.
EmadedinM, LabibzadehN, LiastaniMG, KarimiA, JaroughiN, BoluriehT, HosseiniSE, BaharvandH and AghdamiN. (2018). Intra-articular implantation of autologous bone marrow–derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy, 20:1238–1246.
78.
JonesIA, WilsonM, TogashiR, HanB, MircheffAK and Thomas Vangsness JrC. (2018). A randomized, controlled study to evaluate the efficacy of intra-articular, autologous adipose tissue injections for the treatment of mild-to-moderate knee osteoarthritis compared to hyaluronic acid: a study protocol. BMC Musculoskelet Disord, 19:383.
79.
Lamo-EspinosaJM, MoraG, BlancoJF, Granero-MoltóF, Núñez-CórdobaJM, López-ElíoS, AndreuE, Sánchez-GuijoF, AquerretaJD, et al. (2018). Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II). J Transl Med, 16:213.
80.
MatasJ, OrregoM, AmenabarD, InfanteC, Tapia-LimonchiR, CadizMI, Alcayaga-MirandaF, GonzálezPL, MuseE, et al. (2019). Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Transl Med, 8:215–224.
81.
FreitagJ, BatesD, WickhamJ, ShahK, HugueninL, TenenA, PatersonK and BoydR. (2019). Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regen Med, 14:213–230.
82.
HongZ, ChenJ, ZhangS, ZhaoC, BiM, ChenX and BiQ. (2019). Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. Int Orthop, 43:1123–1134.
83.
Khalifeh SoltaniS, ForoghB, AhmadbeigiN, Hadizadeh KharaziH, FallahzadehK, KashaniL, KaramiM, KheyrollahY and VaseiM. (2019). Safety and efficacy of allogenic placental mesenchymal stem cells for treating knee osteoarthritis: a pilot study. Cytotherapy, 21:54–63.
84.
LeeWS, KimHJ, KimKI, KimGB and JinW. (2019). Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Transl Med, 8:504–511.
85.
LuL, DaiC, ZhangZ, DuH, LiS, YeP, FuQ, ZhangL, WuX, et al. (2019). Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther, 10:143.
86.
ShapiroSA, ArthursJR, HeckmanMG, BesticJM, KazmerchakSE, DiehlNN, ZubairAC and O'ConnorMI. (2019). Quantitative T2 MRI mapping and 12-month follow-up in a randomized, blinded, placebo controlled trial of bone marrow aspiration and concentration for osteoarthritis of the knees. Cartilage, 10:432–443.
87.
BastosR, MathiasM, AndradeR, RAmaralJFC, SchottV, BalduinoA, BastosR, Miguel OliveiraJ, ReisRL, RodeoS and Espregueira-MendesJ. (2020). Intra-articular injection of culture-expanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial. Knee Surg Sports Traumatol Arthrosc, 28:1989–1999.
88.
TranTDX, WuCM, DubeyNK, DengYH, SuCW, PhamTT, Thi LePB, SestiliP and DengWP. (2019). Time- and Kellgren⁻Lawrence grade-dependent changes in intra-articularly transplanted stromal vascular fraction in osteoarthritic patients. Cells, 8:308.
89.
KhasruMR, SalekAM, MarzenT, SiddiqA and IslamM. (2019). Peripheral blood derived stem cells in OA knee at low resource setting: a phase II RCT. Osteoarthritis Cartilage, 27:512.
90.
GarzaJR, CampbellRE, TjoumakarisFP, FreedmanKB, MillerLS, Santa MariaD and TuckerBS. (2020). Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: a double-blinded prospective randomized controlled clinical trial. Am J Sports Med, 48:588–598.
91.
PageMJ, McKenzieJE, BossuytPM, BoutronI, HoffmannTC, MulrowCD, ShamseerL, TetzlaffJM, AklEA, et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372:n71.
92.
YanP, YaoL, LiH, ZhangM, XunY, LiM, CaiH, LuC, HuL, et al. (2019). The methodological quality of robotic surgical meta-analyses needed to be improved: a cross-sectional study. J Clin Epidemiol, 109:20–29.
93.
SiemensW, SchwarzerG, RoheMS, BurohS, MeerpohlJJ and BeckerG. (2021). Methodological quality was critically low in 9/10 systematic reviews in advanced cancer patients-A methodological study. J Clin Epidemiol, 136:84–95.
94.
ImpellizzeriFM, JonesDM, GriffinD, Harris-HayesM, ThorborgK, CrossleyKM, ReimanMP, ScholesMJ, AgebergE, et al. (2020). Patient-reported outcome measures for hip-related pain: a review of the available evidence and a consensus statement from the International Hip-related Pain Research Network, Zurich 2018. Br J Sports Med, 54:848–857.
95.
BicketAK, LeJT, Azuara-BlancoA, GazzardG, WormaldR, BunceC, HuK, JayaramH, KingA, et al. (2021). Minimally invasive glaucoma surgical techniques for open-angle glaucoma: an overview of Cochrane systematic reviews and network meta-analysis. JAMA Ophthalmol, 139:983–989.
96.
SalvoEM, FerkoNC, CashSB, GonzalezA and KahrilasPJ. (2021). Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther, 54:129–143.
97.
GeL, TianJH, LiYN, PanJX, LiG, WeiD, XingX, PanB, ChenYL, SongFJ and YangKH. (2018). Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study. J Clin Epidemiol, 93:45–55.
98.
SideriS, PapageorgiouSN and EliadesT. (2018). Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol, 100:103–110.
99.
DwanK, GambleC, WilliamsonPR, Kirkham and Reporting Bias GroupJJ. (2013). Systematic review of the empirical evidence of study publication bias and outcome reporting bias—an updated review. PLoS One, 8:e66844.
100.
WintersM and WeirA. (2017). Grey matters; on the importance of publication bias in systematic reviews. Br J Sports Med, 51:488–489.
101.
HuangJ, QinX, ShenM, XuY and HuangY. (2021). The effects of Tai Chi exercise among adults with chronic heart failure: an overview of systematic review and meta-analysis. Front Cardiovasc Med, 8:589267.
102.
FortesPM, MarquesSM, VianaKA, CostaLR, NaghettiniAV and CostaPS. (2018). The use of probiotics for improving lipid profiles in dyslipidemic individuals: an overview protocol. Syst Rev, 7:165.
103.
WangX, WangY, WeiS, HeB, CaoY, ZhangN and LiM. (2021). An overview of systematic reviews of acupuncture for infertile women undergoing in vitro fertilization and embryo transfer. Front Public Health, 9:651811.
104.
ZhangJ, YuQ, PengL, QinY, JingM, HuangD, GuoJ, XiaoM and ChenM. (2021). Benefits and safety of Chinese herbal medicine in treating psoriasis: an overview of systematic reviews. Front Pharmacol, 12:680172.
105.
PieperD, PuljakL, González-LorenzoM and MinozziS. (2019). Minor differences were found between AMSTAR 2 and ROBIS in the assessment of systematic reviews including both randomized and nonrandomized studies. J Clin Epidemiol, 108:26–33.
106.
LorenzRC, MatthiasK, PieperD, WegewitzU, MorcheJ, NoconM, RisslingO, SchirmJ and JacobsA. (2019). A psychometric study found AMSTAR 2 to be a valid and moderately reliable appraisal tool. J Clin Epidemiol, 114:133–140.
107.
PerryR, WhitmarshA, LeachV and DaviesP. (2021). A comparison of two assessment tools used in overviews of systematic reviews: ROBIS versus AMSTAR-2. Syst Rev, 10:273.
108.
GatesM, GatesA, DuarteG, CaryM, BeckerM, PredigerB, VandermeerB, FernandesRM, PieperD and HartlingL. (2020). Quality and risk of bias appraisals of systematic reviews are inconsistent across reviewers and centers. J Clin Epidemiol, 125:9–15.
109.
GatesA, GatesM, DuarteG, CaryM, BeckerM, PredigerB, VandermeerB, FernandesRM, PieperD and HartlingL. (2018). Evaluation of the reliability, usability, and applicability of AMSTAR, AMSTAR 2, and ROBIS: protocol for a descriptive analytic study. Syst Rev, 7:85.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
